1. Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
- Author
-
Li, X, Guo, X, Zhu, Y, Wei, G, Zhang, Y, Xu, H, Cui, J, Wu, W, He, J, Ritchie, ME, Weiskittel, TM, Li, H, Yu, H, Ding, L, Shao, M, Luo, Q, Xu, X, Teng, X, Chang, AH, Zhang, J, Huang, H, Hu, Y, Li, X, Guo, X, Zhu, Y, Wei, G, Zhang, Y, Xu, H, Cui, J, Wu, W, He, J, Ritchie, ME, Weiskittel, TM, Li, H, Yu, H, Ding, L, Shao, M, Luo, Q, Xu, X, Teng, X, Chang, AH, Zhang, J, Huang, H, and Hu, Y
- Abstract
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of hematological malignancies due to the prominent anti-tumor effects. B cell maturation antigen (BCMA) CAR-T cells have demonstrated promising effects in patients with relapsed/refractory multiple myeloma. However, the dynamics of CAR-T cell proliferation and cytotoxicity in clinical patients remains unexplored. Here, we longitudinally profiled the transcriptomes of 55,488 T cells including CAR-T products, CAR-T cells, and endogenous T cells at the peak and remission phases in a plasma cell leukemia (PCL) patient treated with BCMA CAR-T cells by single-cell transcriptomic analysis. Our results showed distinct CAR-T and endogenous T cell subsets indicating stage-specific expression in proliferation, cytotoxicity, and intercellular signaling pathways. Furthermore, we found that CAR-T cells at peak phase gradually convert to a highly cytotoxic state from a highly proliferative state along a development trajectory. Moreover, re-analysis of a single cell study from CD8+ CD19 CAR-T confirmed our findings. These commonalities suggest conserved mechanisms for CAR-T treatment across hematological malignancies. Taken together, our current study provides insight into CAR-T cell dynamics during CAR-T therapy and proves that both BCMA CAR-T and CD19 CAR-T have similar transcriptional characteristics, especially at the CAR-T peak phase.
- Published
- 2021